Ovugel Patent Expiration

Ovugel is a drug owned by AURORA PHARMACEUTICAL, INC. It is protected by 9 US drug patents filed from 2017 to 2030. Out of these, 3 patents are active and 6 patents have expired. Details of Ovugel’s patents and their expiration are given below.

Filter patents by

Drug Patent Number Drug Patent Expiry Status
Patent Data
US9352011 23 Apr, 2030 Active
US7205281 30 Sep, 2024 Expired
US9351818 30 Sep, 2024 Expired
US8937044 30 Sep, 2024 Expired
US8530419 30 Sep, 2024 Expired
US5985320 03 Mar, 2022 Expired
USRE 42072 03 Mar, 2017 Expired

Exclusivity Information

Ovugel holds 1 exclusivity out of which 1 has expired. Details of Ovugel's exclusivity codes and their expiration dates are given below.

Drug Exclusivity Drug Exclusivity Expiration
NCE Sep 18, 2017

About Ovugel

Ovugel is a drug owned by AURORA PHARMACEUTICAL, INC. Ovugel uses Triptorelin Acetate as the active ingredient.

Active Ingredient:

Ovugel uses Triptorelin Acetate as the active ingredient. Check out other Drugs and Companies using Triptorelin Acetate ingredient.